Scott Hutton is the President, Chief Executive Officer, and Director of Biodesix, where his personal leadership philosophy centers on inspiring team members to high performance and outstanding results. In 2020, Scott and his leadership team led the IPO for BDSX on the Nasdaq exchange. Since then, Biodesix has grown into a leading lung diagnostics company with a mission to transform the standard of care and improve outcomes through personalized diagnostics.
Scott is a strategic, transformational leader with 25 years of experience in the biotech, diagnostics, and medical device industries. He has a proven track record of successfully developing and leading high performance, cross-functional teams credited with 50+ product launches that have positively impacted tens of millions of patients globally. Prior to being named Biodesix CEO in 2020, Scott held the role of Biodesix Chief Operating Officer. He joined Biodesix from Spectranetics Corp, now part of Royal Philips, where he served as Senior Vice President and General Manager of the Vascular Intervention division. Prior to Spectranetics, Scott spent over 16 years at Medtronic in a variety of roles and medical specialties, including Vice President and General Manager of the Neurosurgery Business Unit, where he drove the business to many consecutive years of high double-digit growth and market share leadership.
Scott is a Purdue University alumnus with a 1995 Bachelor of Arts degree from the College of Health and Human Sciences, Department of Health and Kinesiology. Scott was recently appointed by the Purdue University College of Health and Human Sciences Dean’s Leadership Council (2025-2028) to offer strategic insight, mentorship, and support to help guide the college’s direction. Scott also currently serves on the Coalition for 21st Century Medicine (C21) Board of Directors and the Eximis Surgical Board of Directors.